Propanc Biopharma (NASDAQ:PPCB) Stock Jumps 0.8% – Time to Buy?

Propanc Biopharma Inc (NASDAQ:PPCB)’s stock price traded up 0.8% during mid-day trading on Thursday. The stock traded as high as $1.99 and last traded at $1.8550. Approximately 21,769 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 39,323 shares. The stock had previously closed at $1.84.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Propanc Biopharma Stock Up 0.8%

The firm has a market capitalization of $1.17 million, a PE ratio of -0.01 and a beta of 3.55. The business’s fifty day moving average price is $4.73 and its 200 day moving average price is $20.69.

Propanc Biopharma (NASDAQ:PPCB) last released its earnings results on Friday, September 25th. The company reported ($17.74) earnings per share (EPS) for the quarter.

About Propanc Biopharma

Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen.